Nanox Imaging will report Q2 2025 financial results on August 12, with a conference call scheduled for 8:30 a.m. ET.
Quiver AI Summary
NANO-X IMAGING LTD (Nanox), an innovative medical imaging technology company based in Israel, announced it will release its financial results for the quarter ending June 30, 2025, on August 12, 2025, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will discuss these results and provide a business update in a conference call at 8:30 a.m. ET, with registration available online. Nanox focuses on advancing preventive healthcare through affordable medical imaging technologies, utilizing AI and a proprietary digital X-ray source. Their products include the cost-effective Nanox.ARC system, AI algorithms to improve CT imaging diagnostics, a cloud-based data management platform, and a decentralized marketplace for radiology services. Nanox's mission is to enhance health outcomes globally through early detection and treatment.
Potential Positives
- Nano-X Imaging Ltd will report its financial results for Q2 2025, indicating transparency and accountability to investors.
- The upcoming conference call with the CEO and CFO is an opportunity for investors to gain insights into the company's performance and strategic direction.
- Nano-X’s focus on affordable medical imaging technologies and AI positions the company as an innovator in the healthcare sector, potentially expanding its market reach.
- The diverse ecosystem of products, including Nanox.ARC, Nanox.AI, and Nanox.CLOUD, showcases the company's commitment to enhancing healthcare outcomes through integrated technology solutions.
Potential Negatives
- Failure to disclose prior financial performance could raise concerns about the company's transparency and the stability of its financial health.
- The announcement of upcoming financial results without prior context may indicate potential uncertainty or challenges within the company's operations that stakeholders need to be cautious about.
- Hosting a conference call to review financial results may imply that previous announcements did not meet investor expectations, leading to potential skepticism about the company's future performance.
FAQ
When will Nanox report its Q2 2025 financial results?
Nanox will report its financial results for the quarter ended June 30, 2025, on Tuesday, August 12, 2025.
Who will host the conference call for Nanox's financial results?
The conference call will be hosted by Erez Meltzer, CEO, and Ran Daniel, CFO of Nanox.
What time is the Nanox Q2 2025 conference call?
The conference call will begin at 8:30 a.m. ET on August 12, 2025.
How can I access the Nanox Q2 2025 conference call?
Interested parties can register for the conference call using a provided link and access the live webcast online.
What is the focus of Nanox as a company?
Nanox is dedicated to advancing preventive health care through affordable medical imaging technologies leveraging AI and digital X-ray innovations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NNOX Hedge Fund Activity
We have seen 55 institutional investors add shares of $NNOX stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,510,806 shares (+232.4%) to their portfolio in Q1 2025, for an estimated $7,546,475
- MORGAN STANLEY removed 589,364 shares (-44.0%) from their portfolio in Q1 2025, for an estimated $2,943,873
- NATIONAL BANK OF CANADA /FI/ added 325,600 shares (+1170.0%) to their portfolio in Q1 2025, for an estimated $1,626,372
- BALYASNY ASSET MANAGEMENT L.P. added 146,366 shares (+758.6%) to their portfolio in Q1 2025, for an estimated $731,098
- UBS GROUP AG added 127,720 shares (+9.0%) to their portfolio in Q1 2025, for an estimated $637,961
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 123,502 shares (-64.8%) from their portfolio in Q1 2025, for an estimated $616,892
- BLACKROCK, INC. removed 107,103 shares (-3.1%) from their portfolio in Q1 2025, for an estimated $534,979
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NNOX Analyst Ratings
Wall Street analysts have issued reports on $NNOX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 06/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/01/2025
To track analyst ratings and price targets for $NNOX, check out Quiver Quantitative's $NNOX forecast page.
$NNOX Price Targets
Multiple analysts have issued price targets for $NNOX recently. We have seen 2 analysts offer price targets for $NNOX in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $10.0 on 06/06/2025
- Ross Osborn from Cantor Fitzgerald set a target price of $9.0 on 04/01/2025
Full Release
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2025, before market open on Tuesday, August 12, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Interested parties may register for the conference call using the following link: Nanox Q2 2025 Conference Call . The live webcast of the conference call may be accessed by using the following link : Nanox Q2 2025 Webcast .
The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations .
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD, a subsidiary of Nanox Imaging, with an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision .
Contacts
Investor Contact
Mike Cavanaugh
ICR Healthcare
[email protected]
Media Contact
ICR Healthcare
[email protected]
